Literature DB >> 9294871

Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: crystal structure of a Fab fragment in complex with a fluorescein-conjugated peptide.

J M van den Elsen1, J N Herron, P Hoogerhout, J T Poolman, E Boel, T Logtenberg, J Wilting, D J Crommelin, J Kroon, P Gros.   

Abstract

Class 1 outer membrane protein PorA of Neisseria meningitidis is a vaccine candidate against bacterial meningitis. Antibodies against PorA are able to induce complement-mediated bacterial killing and thereby play an important role in protection against meningococcal disease. Bactericidal antibodies are all directed against variable regions VR1 and VR2 of the PorA sequence, corresponding to loops 1 and 4 of a two-dimensional topology model of the porin with eight extracellular loops. We have determined the crystal structure to 2.6 A resolution of the Fab fragment of bactericidal antibody MN12H2 against meningococcal PorA in complex with a linear fluorescein-conjugated peptide TKDTNNNL derived from the VR2 sequence of sero-subtype P1.7,16 (residues 180-187) from meningococcal strain H44/76. The peptide folds deeply into the binding cavity of the Fab molecule in a type I beta-turn, with the minimal P1.16 epitope DTNNN virtually completely buried. The structure reveals H-bonds and van der Waals interactions with all minimal epitope residues and one essential salt bridge between Asp-182 of the peptide and His-31 of the MN12H2 light chain. The key components of the recognition of PorA epitope P1.16 by bactericidal antibody MN12H2 correspond well with available thermodynamic data from binding studies. Furthermore, they indicate the structural basis of an increased endemic incidence of infection by group B meningococci in England and Wales since 1981 associated with the occurrence of an Neisseria meningitidis escape mutant (strain-MC58). The observed three-dimensional conformation of the peptide provides a rationale for the development of a synthetic peptide vaccine against meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294871     DOI: 10.1002/(sici)1097-0134(199709)29:1<113::aid-prot9>3.3.co;2-u

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  5 in total

1.  Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis.

Authors:  J Wang; G A Jarvis; M Achtman; E Rosenqvist; T E Michaelsen; A Aase; J M Griffiss
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Authors:  Elisabeth Wedege; Betsy Kuipers; Karin Bolstad; Harry van Dijken; L Oddvar Frøholm; Clementien Vermont; Dominique A Caugant; Germie van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  Structure-based design of chimeric antigens for multivalent protein vaccines.

Authors:  S Hollingshead; I Jongerius; R M Exley; S Johnson; S M Lea; C M Tang
Journal:  Nat Commun       Date:  2018-03-13       Impact factor: 14.919

Review 4.  The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment.

Authors:  Martin Christopher James Maiden
Journal:  Front Immunol       Date:  2019-01-15       Impact factor: 7.561

5.  Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp.

Authors:  Jacinto López-Sagaseta; Peter T Beernink; Federica Bianchi; Laura Santini; Elisabetta Frigimelica; Alexander H Lucas; Mariagrazia Pizza; Matthew J Bottomley
Journal:  Nat Commun       Date:  2018-02-06       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.